Stage II Breast Cancer
120
7
22
61
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
45 trials with published results (38%)
Research Maturity
61 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
24 terminated out of 120 trials
71.8%
-14.7% vs benchmark
8%
9 trials in Phase 3/4
74%
45 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 61 completed trials
Clinical Trials (120)
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Researching the Effect of Exercise on Cancer
A Study of Revaree Plus in People With Breast Cancer
Window of Opportunity Study Targeting the Inflammatory Milieu
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer